- Home
- MAC vs KRYS Comparison
MAC vs KRYS Comparison
Compare MAC & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAC
- KRYS
- Stock Information
- Founded
- MAC 1964
- KRYS 2015
- Country
- MAC United States
- KRYS United States
- Employees
- MAC N/A
- KRYS N/A
- Industry
- MAC Real Estate Investment Trusts
- KRYS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAC Real Estate
- KRYS Health Care
- Exchange
- MAC Nasdaq
- KRYS Nasdaq
- Market Cap
- MAC 4.7B
- KRYS 4.7B
- IPO Year
- MAC 1994
- KRYS 2017
- Fundamental
- Price
- MAC $17.91
- KRYS $184.87
- Analyst Decision
- MAC Buy
- KRYS Strong Buy
- Analyst Count
- MAC 12
- KRYS 9
- Target Price
- MAC $19.87
- KRYS $210.22
- AVG Volume (30 Days)
- MAC 2.2M
- KRYS 283.0K
- Earning Date
- MAC 11-04-2025
- KRYS 11-03-2025
- Dividend Yield
- MAC 3.89%
- KRYS N/A
- EPS Growth
- MAC N/A
- KRYS 36.22
- EPS
- MAC N/A
- KRYS 4.91
- Revenue
- MAC $1,049,150,000.00
- KRYS $359,205,000.00
- Revenue This Year
- MAC $12.09
- KRYS $34.33
- Revenue Next Year
- MAC $0.30
- KRYS $47.84
- P/E Ratio
- MAC N/A
- KRYS $38.10
- Revenue Growth
- MAC 32.06
- KRYS 116.08
- 52 Week Low
- MAC $12.48
- KRYS $122.80
- 52 Week High
- MAC $22.27
- KRYS $207.84
- Technical
- Relative Strength Index (RSI)
- MAC 56.37
- KRYS 57.07
- Support Level
- MAC $16.84
- KRYS $186.73
- Resistance Level
- MAC $17.45
- KRYS $196.78
- Average True Range (ATR)
- MAC 0.45
- KRYS 6.67
- MACD
- MAC 0.07
- KRYS -1.07
- Stochastic Oscillator
- MAC 79.72
- KRYS 33.30
About MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 29 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with two power centers and seven other real estate assets. The company's total portfolio has 42.1 million square feet of gross leasable area and averaged $837 sales per square foot over the 12 months ended in March 2025.
About KRYS Krystal Biotech Inc.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.